NEW YORK (GenomeWeb) – CombiMatrix said today that that the New York State Department of Health has approved its next-generation sequencing pre-implantation genetic screening test.

The company's CombiPGS test screens embryo biopsy cells for chromosomal abnormalities prior to implantation in women undergoing in vitro fertilization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.